{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:49:45Z","timestamp":1791614985015,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Chronic kidney disease (CKD) patients show high rates of cardiovascular disease (CVD) and mortality. In the general population, obesity, hypertension, and diabetes are known as the classical CVD risk factors. However, CKD patients have other predisposing CVD factors more associated with bone and mineral metabolism disorders (BMD). BMD originates from reduced 1,25-dihydroxy vitamin D and hypocalcemia, which lead to secondary hyperparathyroidism, with increased parathyroid hormone (PTH) levels and hyperphosphatemia as the progression of renal damage. Due to their pleiotropic effects, vitamin D and its analogs, such as cholecalciferol, calcitriol, or paricalcitol, have proven effective in controlling BMD and CVD. On the other hand, visceral adiposity has been shown to increase the risk for CVD in both the general and CKD populations via complex autocrine and paracrine hormonal mechanisms. This seems to be the case with fat surrounding the epicardium. Although it has not been widely evaluated, the fat surrounding the kidneys, or the perirenal adipose tissue (PAT), could also share similarities with the epicardial in terms of its potential contribution to the CVD risk observed in these patients. We conducted a preliminary study to assess differences in PAT on a sample of patients with CKD presenting diverse CVD history and who were receiving different vitamin D-receptor activators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Results<\/jats:title>\n            <jats:p>An observational study was performed at UNIRENAL Center (Venezuela), from January to November 2015. Analytical and clinical parameters were evaluated. The PAT thickness was measured in centimeters through a B-mode ultrasound. Thus, we included 83 CKD patients treated with vitamin D or analogs (mean age 58.3\u2009\u00b1\u200916y); 57.83% were females. Nearly half of the sample was classified as CKD-G3 (<jats:italic>n<\/jats:italic>\u2009=\u200940). Prior history of CVD was present in 55.4% (<jats:italic>N<\/jats:italic>\u2009=\u200946) of participants. Must of the patients (<jats:italic>n<\/jats:italic>\u2009=\u200946;55.42%) receiving oral cholecalciferol (1000 IU\/day) as part of the treatment for lower levels of vitamin D or BMD related to CKD (mainly elevated PTH), followed by those under calcitriol at 0.5 mcg\/day (<jats:italic>n<\/jats:italic>\u2009=\u200927;32.53%), and around 12% (<jats:italic>n<\/jats:italic>\u2009=\u200910;12.05%) on paricalcitol (1 mcg\/day). The mean treatment vintage was 20\u2009\u00b1\u20096 months for cholecalciferol, 18\u2009\u00b1\u20094 months for calcitriol, and 16\u2009\u00b1\u20092 months for paricalcitol. Those with a history of CVD (<jats:italic>n<\/jats:italic>\u2009=\u200946) showed higher levels of urea (mean 62.0vs45.2\u00a0mg\/dl, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), uric acid (mean 5.5vs4.3\u00a0mg\/dl; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.03), and iPTH (mean 186.2vs65.2pcg\/dl; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) than patients free of CVD events (<jats:italic>n<\/jats:italic>\u2009=\u200937). These findings were also in parallel with decreased renal function in the group with previous CVD history, as evidenced by a significantly lower eGFR (mean 53.55vs89.00\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup>,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Similarly, the mean PAT thickness was elevated in the group with a history of CVD in relation to those with no previous CVD events (0.99vs0.80\u00a0cm; SD\u2009\u00b1\u20090.30;<jats:italic>p<\/jats:italic>\u2009~\u20090.05). The comparative analysis for the patients with prior cardiovascular events between the three treatments revealed that those on paricalcitol had lesser PAT accumulation than those treated with cholecalciferol or calcitriol (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In conclusion, our study shows that PAT thickness in CKD may be influenced by vitamin D analog-based treatment. Further research is needed to better understand the mechanistic links between PAT, BMD, and CVD in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12882-025-04041-2","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T19:26:27Z","timestamp":1741202787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perirenal fat differs in patients with chronic kidney disease receiving different vitamin D-based treatments: a preliminary study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ana","family":"Checa-Ros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Locascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owahabanun-Joshua","family":"Okojie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Abell\u00e1n-Galiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"D\u2019Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"5","key":"4041_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","volume":"42","author":"MJ Sarnak","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42(5):1050\u201365.","journal-title":"Hypertension"},{"issue":"1","key":"4041_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40620-020-00842-w","volume":"34","author":"G Deferrari","year":"2021","unstructured":"Deferrari G, Cipriani A, La Porta E. Renal dysfunction in cardiovascular diseases and its consequences. J Nephrol. 2021;34(1):137\u201353.","journal-title":"J Nephrol"},{"issue":"1","key":"4041_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11892-010-0162-y","volume":"11","author":"PA McCullough","year":"2011","unstructured":"McCullough PA, Steigerwalt S, Tolia K, Chen SC, Li S, Norris KC, et al. Cardiovascular disease in chronic kidney disease: data from the kidney early evaluation program (KEEP). Curr Diab Rep. 2011;11(1):47\u201355.","journal-title":"Curr Diab Rep"},{"issue":"9889","key":"4041_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339\u201352.","journal-title":"Lancet"},{"key":"4041_CR5","doi-asserted-by":"crossref","unstructured":"Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS ONE. 2018;13(3).","DOI":"10.1371\/journal.pone.0192895"},{"key":"4041_CR6","doi-asserted-by":"publisher","first-page":"100437","DOI":"10.1016\/j.clinsp.2024.100437","volume":"79","author":"L Li","year":"2024","unstructured":"Li L, Zhao J. Association of serum 25-hydroxyvitamin D with cardiovascular and all-cause mortality in patients with chronic kidney disease: NHANES 2007\u20132018 results. Clinics. 2024;79:100437.","journal-title":"Clinics"},{"issue":"3","key":"4041_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.ki.5002287","volume":"74","author":"WG Goodman","year":"2008","unstructured":"Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276\u201388.","journal-title":"Kidney Int"},{"issue":"4","key":"4041_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00223-020-00777-1","volume":"108","author":"JB Cannata-And\u00eda","year":"2021","unstructured":"Cannata-And\u00eda JB, Mart\u00edn-Carro B, Mart\u00edn-V\u00edrgala J, Rodr\u00edguez-Carrio J, Bande-Fern\u00e1ndez JJ, Alonso-Montes C, et al. Chronic kidney Disease\u2014Mineral and bone disorders: pathogenesis and management. Calcif Tissue Int. 2021;108(4):410\u201322.","journal-title":"Calcif Tissue Int"},{"key":"4041_CR9","doi-asserted-by":"crossref","unstructured":"Bover J, Ure\u00f1a-Torres P, G\u00f3rriz JL, Lloret MJ, da Silva I, Ruiz-Garc\u00eda C et al. Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. Vol. 36, Nefrologia. Elsevier Espana S.L.; 2016. pp. 597\u2013608.","DOI":"10.1016\/j.nefroe.2016.12.011"},{"key":"4041_CR10","doi-asserted-by":"crossref","unstructured":"Torres PAU, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int [Internet]. 2012;82(1):19\u201325. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22437409","DOI":"10.1038\/ki.2012.69"},{"issue":"1","key":"4041_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11154-017-9421-4","volume":"18","author":"MR Portillo","year":"2017","unstructured":"Portillo MR, Rodr\u00edguez-Ortiz ME. Secondary hyperparthyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):79\u201395.","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"4041_CR12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1681\/ASN.2007111164","volume":"19","author":"AB Shoben","year":"2008","unstructured":"Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol. 2008;19(8):1613\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"4041_CR13","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/ndt\/gft227","volume":"28","author":"DW Coyne","year":"2013","unstructured":"Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dialysis Transplantation. 2013;28(9):2260\u20138.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"3","key":"4041_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/0272-6386(95)90118-3","volume":"25","author":"EM Brown","year":"1995","unstructured":"Brown EM, Pollak M, Hebert SC. Sensing of extracellular Ca2\u2009+\u2009by parathyroid and kidney cells: cloning and characterization of an extracellular Ca2+-sensing receptor. Am J Kidney Dis. 1995;25(3):506\u201313.","journal-title":"Am J Kidney Dis"},{"key":"4041_CR15","doi-asserted-by":"crossref","unstructured":"Messa P, Maca[Combining Acute Accent]rio F, Yaqoob M, Bouman K, Braun J, von Albertini B et al. The OPTIMA Study. Clinical Journal of the American Society of Nephrology. 2008;3(1):36\u201345.","DOI":"10.2215\/CJN.03591006"},{"issue":"4","key":"4041_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000350213","volume":"37","author":"RD Kilpatrick","year":"2013","unstructured":"Kilpatrick RD, Newsome BB, Zaun D, Liu J, Solid CA, Nieman K, et al. Evaluating Real-World use of Cinacalcet and biochemical response to therapy in US Hemodialysis patients. Am J Nephrol. 2013;37(4):389\u201398.","journal-title":"Am J Nephrol"},{"issue":"4","key":"4041_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/ndt\/gfad213","volume":"39","author":"S Goto","year":"2024","unstructured":"Goto S, Hamano T, Fujii H, Taniguchi M, Abe M, Nitta K, et al. Hypocalcemia and cardiovascular mortality in Cinacalcet users. Nephrol Dialysis Transplantation. 2024;39(4):637\u201347.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"4041_CR18","doi-asserted-by":"crossref","unstructured":"Mathieu P, Poirier P, Pibarot P, Lemieux I, Despr\u00e9s JP. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension [Internet]. 2009;53(4):577\u201384. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19237685","DOI":"10.1161\/HYPERTENSIONAHA.108.110320"},{"issue":"Cvd","key":"4041_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1291537","volume":"2016","author":"J Salazar","year":"2016","unstructured":"Salazar J, Luzardo E, Mej\u00edas JC, Rojas J, Ferreira A, Rivas-R\u00edos JR, et al. Epicardial fat: physiological, pathological, and therapeutic implications. Cardiol Res Pract. 2016;2016(Cvd):1\u201315.","journal-title":"Cardiol Res Pract"},{"key":"4041_CR20","doi-asserted-by":"crossref","unstructured":"D\u2019Marco L, Puchades MJ, Panizo N, Romero-Parra M, Gand\u00eda L, Gim\u00e9nez-Civera E et al. Cardiorenal fat: A cardiovascular risk factor with implications in chronic kidney disease. Front Med (Lausanne). 2021;(8):640814","DOI":"10.3389\/fmed.2021.640814"},{"issue":"3","key":"4041_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.23876\/j.krcp.18.0155","volume":"38","author":"L D\u2019Marco","year":"2019","unstructured":"D\u2019Marco L, Salazar J, Cortez M, Salazar M, Wettel M, Lima-Mart\u00ednez M, et al. Perirenal fat thickness is associated with metabolic risk factors in patients with chronic kidney disease. Kidney Res Clin Pract. 2019;38(3):365\u201372.","journal-title":"Kidney Res Clin Pract"},{"issue":"7","key":"4041_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/0003319718799967","volume":"70","author":"BX Liu","year":"2019","unstructured":"Liu BX, Sun W, Kong XQ. Perirenal fat: A unique fat pad and potential target for cardiovascular disease. Angiology. 2019;70(7):584\u201393.","journal-title":"Angiology"},{"key":"4041_CR23","doi-asserted-by":"crossref","unstructured":"TANUMA Y, YAMAMOTO M, ITO T. YOKOCHI C. The occurrence of brown adipose tissue in perirenal fat in Japanese. Arch Histologicum Japonicum. 1975;38(1).","DOI":"10.1679\/aohc1950.38.43"},{"key":"4041_CR24","doi-asserted-by":"publisher","unstructured":"Jespersen NZ, Feizi A, Andersen ES, Heywood S, Hattel HB, Daugaard S et al. Heterogeneity in the perirenal region of humans suggests presence of dormant brown adipose tissue that contains brown fat precursor cells. Mol Metab [Internet]. 2019;24(March):30\u201343. Available from: https:\/\/doi.org\/10.1016\/j.molmet.2019.03.005","DOI":"10.1016\/j.molmet.2019.03.005"},{"issue":"2","key":"4041_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cmet.2015.06.004","volume":"22","author":"X Hui","year":"2015","unstructured":"Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, et al. Adiponectin enhances Cold-Induced Browning of subcutaneous adipose tissue via promoting M2 macrophage proliferation. Cell Metab. 2015;22(2):279\u201390.","journal-title":"Cell Metab"},{"key":"4041_CR26","doi-asserted-by":"crossref","unstructured":"Koo BK, Denenberg JO, Wright CM, Criqui MH, Allison MA. Associations of perirenal fat thickness with renal and systemic calcified atherosclerosis. Endocrinol Metabolism. 2020;35(1).","DOI":"10.3803\/EnM.2020.35.1.122"},{"key":"4041_CR27","doi-asserted-by":"crossref","unstructured":"Bassols J, Mart\u00ednez-Calcerrada JM, Prats-Puig A, Carreras-Badosa G, Xargay-Torrent S, Lizarraga-Mollinedo E et al. Perirenal fat is related to carotid intima-media thickness in children. Int J Obes. 2018;42(4).","DOI":"10.1038\/ijo.2017.236"},{"key":"4041_CR28","doi-asserted-by":"crossref","unstructured":"Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, Rooney CM et al. Fibroblast growth Factor-23 and risks of cardiovascular and noncardiovascular diseases: A Meta-Analysis. J Am Soc Nephrol. 2018;29(7).","DOI":"10.1681\/ASN.2017121334"},{"key":"4041_CR29","doi-asserted-by":"crossref","unstructured":"Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res [Internet]. 2010;25(8):1711\u201323. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20200981","DOI":"10.1002\/jbmr.65"},{"key":"4041_CR30","doi-asserted-by":"crossref","unstructured":"Spoto B, Pizzini P, Tripepi G, Mallamaci F, Zoccali C. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Nephrol Dial Transplant [Internet]. 2018;33(10):1764\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29304245","DOI":"10.1093\/ndt\/gfx344"},{"key":"4041_CR31","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.12659\/MSM.904755","volume":"23","author":"X Chen","year":"2017","unstructured":"Chen X, Wu W, Wang L, Shi Y, Shen F, Gu X, et al. Association between 25-Hydroxyvitamin D and epicardial adipose tissue in Chinese Non-Obese patients with type 2 diabetes. Med Sci Monit. 2017;23:4304\u201311.","journal-title":"Med Sci Monit"},{"issue":"6","key":"4041_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.5551\/jat.28381","volume":"22","author":"KM Gurses","year":"2015","unstructured":"Gurses KM, Tokgozoglu L, Yalcin MU, Kocyigit D, Evranos B, Yorgun H, et al. Epicardial fat thickness is increased in vitamin D deficient premenopausal women and does not decrease after Short-term replacement. J Atheroscler Thromb. 2015;22(6):582\u20139.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"4041_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.yexmp.2012.04.006","volume":"93","author":"GK Gupta","year":"2012","unstructured":"Gupta GK, Agrawal T, DelCore MG, Mohiuddin SM, Agrawal DK. Vitamin D deficiency induces cardiac hypertrophy and inflammation in epicardial adipose tissue in hypercholesterolemic swine. Exp Mol Pathol. 2012;93(1):82\u201390.","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"4041_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.numecd.2014.08.012","volume":"25","author":"E Dozio","year":"2015","unstructured":"Dozio E, Briganti S, Vianello E, Dogliotti G, Barassi A, Malavazos AE, et al. Epicardial adipose tissue inflammation is related to vitamin D deficiency in patients affected by coronary artery disease. Nutr Metabolism Cardiovasc Dis. 2015;25(3):267\u201373.","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"4","key":"4041_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10554-015-0622-1","volume":"31","author":"M Sunbul","year":"2015","unstructured":"Sunbul M, Bozbay M, Mammadov C, Cincin A, Atas H, Ozsenel EB, et al. Effect of vitamin D deficiency and supplementation on myocardial deformation parameters and epicardial fat thickness in patients free of cardiovascular risk. Int J Cardiovasc Imaging. 2015;31(4):765\u201372.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"10","key":"4041_CR36","doi-asserted-by":"publisher","first-page":"e0199411","DOI":"10.1371\/journal.pone.0199411","volume":"13","author":"P Gunasekar","year":"2018","unstructured":"Gunasekar P, Swier VJ, Fleegel JP, Boosani CS, Radwan MM, Agrawal DK. Vitamin D and macrophage polarization in epicardial adipose tissue of atherosclerotic swine. PLoS ONE. 2018;13(10):e0199411.","journal-title":"PLoS ONE"},{"issue":"1","key":"4041_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41387-024-00297-z","volume":"14","author":"X Zheng","year":"2024","unstructured":"Zheng X, Huang Y, Yang M, Jin L, Zhang X, Zhang R, et al. Vitamin D is involved in the effects of the intestinal flora and its related metabolite TMAO on perirenal fat and kidneys in mice with DKD. Nutr Diabetes. 2024;14(1):42.","journal-title":"Nutr Diabetes"},{"key":"4041_CR38","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","volume":"76","author":"KU Eckardt","year":"2009","unstructured":"Eckardt KU, Kasiske BL. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76:S1\u20132.","journal-title":"Kidney Int"},{"issue":"6","key":"4041_CR39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s12350-013-9761-8","volume":"20","author":"C Karohl","year":"2013","unstructured":"Karohl C, D\u2019Marco L, Bellasi A, Raggi P. Hybrid myocardial imaging for risk stratification prior to kidney transplantation: added value of coronary calcium and epicardial adipose tissue. J Nuclear Cardiol. 2013;20(6):1013\u201320.","journal-title":"J Nuclear Cardiol"},{"issue":"5","key":"4041_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41574-023-00832-5","volume":"19","author":"A new Article","year":"2023","unstructured":"A new Article. Series for adipose tissue. Nat Rev Endocrinol. 2023;19(5):249\u2013249.","journal-title":"Nat Rev Endocrinol"},{"key":"4041_CR41","doi-asserted-by":"crossref","unstructured":"Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant [Internet]. 2010;25(9):2850\u201365. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20525641","DOI":"10.1093\/ndt\/gfq313"},{"key":"4041_CR42","doi-asserted-by":"crossref","unstructured":"Skaaby T, Husemoen LLN, Thuesen BH, Pisinger C, J\u00f8rgensen T, Roswall N et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev [Internet]. 2014;23(7):1220\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24789846","DOI":"10.1158\/1055-9965.EPI-14-0007"},{"key":"4041_CR43","doi-asserted-by":"publisher","unstructured":"Anderson JL, Vanwoerkom RC, Horne BD. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors? Am Heart J [Internet]. 2011;162(2):331\u2013339.e2. Available from: https:\/\/doi.org\/10.1016\/j.ahj.2011.05.005","DOI":"10.1016\/j.ahj.2011.05.005"},{"issue":"5","key":"4041_CR44","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.4049\/jimmunol.173.5.2909","volume":"173","author":"TT Wang","year":"2004","unstructured":"Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909\u201312.","journal-title":"J Immunol"},{"issue":"9","key":"4041_CR45","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2217\/fmb.09.87","volume":"4","author":"AF Gombart","year":"2009","unstructured":"Gombart AF. The vitamin D\u2013Antimicrobial peptide pathway and its role in protection against infection. Future Microbiol. 2009;4(9):1151\u201365.","journal-title":"Future Microbiol"},{"issue":"3","key":"4041_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nep.12029","volume":"18","author":"LM Ong","year":"2013","unstructured":"Ong LM, Narayanan P, Goh HK, Manocha AB, Ghazali A, Omar M, et al. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology. 2013;18(3):194\u2013200.","journal-title":"Nephrology"},{"issue":"3","key":"4041_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10157-013-0844-2","volume":"18","author":"EJ Jamaluddin","year":"2014","unstructured":"Jamaluddin EJ, Gafor AHA, Yean LC, Cader R, Mohd R, Kong NCT, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2014;18(3):507\u201314.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"4041_CR48","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus Cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dialysis Transplantation. 2012;27(8):3270\u20138.","journal-title":"Nephrol Dialysis Transplantation"},{"key":"4041_CR49","doi-asserted-by":"crossref","unstructured":"Navarro-Gonz\u00e1lez JF, Donate-Correa J, M\u00e9ndez ML, de Fuentes MM, Garc\u00eda-P\u00e9rez J, Mora-Fern\u00e1ndez C. Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. J Clin Pharmacol [Internet]. 2013;53(4):421\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23426718","DOI":"10.1002\/jcph.19"},{"key":"4041_CR50","doi-asserted-by":"crossref","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension [Internet]. 2008;52(2):249\u201355. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18606901","DOI":"10.1161\/HYPERTENSIONAHA.108.113159"},{"issue":"1","key":"4041_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/healthcare11010072","volume":"11","author":"L D\u2019Marco","year":"2022","unstructured":"D\u2019Marco L, Checa-Ros A, Gamero D, Soto C, Salazar J, Nava M, et al. Etelcalcetide and paricalcitol in chronic kidney disease: when the target is inflammation. Healthcare. 2022;11(1):72.","journal-title":"Healthcare"},{"key":"4041_CR52","doi-asserted-by":"crossref","unstructured":"Cirilo MA, de Ribeiro S, Lima FPB, Silva NK dos, Gomes JK, Albuquerque JA et al. JSS,. Paricalcitol prevents renal tubular injury induced by ischemia-reperfusion: Role of oxidative stress, inflammation and AT1R. Mol Cell Endocrinol. 2024;594:112349.","DOI":"10.1016\/j.mce.2024.112349"},{"issue":"5","key":"4041_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4132\/jptm.2024.07.12","volume":"58","author":"AL Deluque","year":"2024","unstructured":"Deluque AL, de Almeida LF, Oliveira BM, Souza CS, Maciel ALD, Francescato HDC, et al. Paricalcitol prevents MAPK pathway activation and inflammation in adriamycin-induced kidney injury in rats. J Pathol Transl Med. 2024;58(5):219\u201328.","journal-title":"J Pathol Transl Med"},{"key":"4041_CR54","doi-asserted-by":"publisher","first-page":"108747","DOI":"10.1016\/j.intimp.2022.108747","volume":"108","author":"J Huang","year":"2022","unstructured":"Huang J, Zhang P, An Q, He L, Wang L. New insights into the treatment mechanisms of vitamin D on PM2.5-induced toxicity and inflammation in mouse renal tubular epithelial cells. Int Immunopharmacol. 2022;108:108747.","journal-title":"Int Immunopharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04041-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T07:04:33Z","timestamp":1741244673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04041-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4041"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04041-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Biomedical Research from Puerto Ordaz Hospital (Venezuela). All procedures were performed in accordance with the Declaration of Helsinki as revised in 2013. Verbal and written informed consent was obtained from all subjects involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}